Exero Medical's prospective, blinded, multi-center study of xBar has been approved by the WCG Clinical Services.
Follow Israel Hayom on Facebook, Twitter, and Instagram
The study, expected to commence during Q1 2024 at several leading US and Israeli hospitals, will enroll about 190 patients undergoing colorectal resection. It will evaluate the performance of Exero Medical's flagship device, xBar, in accurately monitoring tissue healing during post-operative recovery to enable the early detection of major complications, such as anastomotic leaks, and the application of enhanced recovery protocols.
This new approach to personalized care for patients undergoing gastrointestinal surgery is intended to enhance surgical outcomes and reduce hospital costs. Exero Medical CEO Dr. Erez Shor said, "We have developed the xBar system as a way to translate a wealth of physiological data, which has been hidden to date for the most part, into tangible, actionable clinical data. Our goal is to empower the clinical team to provide precise, personalized care on time, avoid conditions that are likely to become dire and optimize hospital stays."
